PMV Pharmaceuticals, Inc.
PMVP evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for PMVP—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PMVP
PMV Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule drugs targeting p53 mutations, with its lead candidate PC14586 in a Phase 1/2 trial for solid tumors with the p53 Y220C mutation.
Key risk: Cash runway limited
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 2 clinical trials for PMV Pharmaceuticals, Inc..
PMV Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule drugs targeting p53 mutations, with its lead candidate PC14586 in a Phase 1/2 trial for solid tumors with the p53 Y220C mutation.
- Lead product candidate PC14586 is in a Phase 1/2 clinical trial for patients with locally advanced or metastatic solid tumors harboring a p53 Y220C mutation, with FDA Fast Track Designation granted in October 2020 [sec_mda · as of 2023-11-09].
- The company completed enrollment for the primary analysis in the Phase 2 monotherapy portion of the PYNNACLE study for platinum-resistant/refractory ovarian cancer and plans to submit an initial NDA via accelerated approval in the first quarter of 2027 [sec_mda · as of 2026-08-14].
- As of June 30, 2026, the company reported cash and equivalents of $12.5M, net income of -$18.1M, and shareholders' equity of $104.7M [sec].
- The company expects its cash runway to fund planned operations until the end of the second quarter of 2027, based on assumptions that may prove incorrect [sec_mda · as of 2026-03-06].
- The company has no approved products and continues to incur significant research and development and general administrative expenses [sec_mda · as of 2023-11-09].
What works
- PC14586 has received FDA Fast Track Designation, which may expedite development and review [sec_mda · as of 2023-11-09].
- The company has completed enrollment for the primary analysis in the Phase 2 monotherapy portion for platinum-resistant/refractory ovarian cancer, a key step toward a planned NDA submission [sec_mda · as of 2026-08-14].
- The company has an End-of-Phase 1 FDA meeting with alignment on the recommended Phase 2 dose and key elements of the registrational portion of the PYNNACLE study, indicating regulatory alignment [sec_mda · as of 2023-11-09].
What to weigh
- The company has no approved products and has incurred significant net losses, with a net income of -$18.1M as of June 30, 2026 [sec].
- Cash runway is estimated only until the end of the second quarter of 2027, and the company may need additional financing to complete development and commercialization [sec_mda · as of 2026-03-06].
- Clinical development timelines, probability of success, and costs are unpredictable and can differ materially from expectations [sec_mda · as of 2025-11-12].
- The company expects operating expenses to increase significantly as it advances product candidates through preclinical and clinical development, seeks regulatory approval, and prepares for commercialization [sec_mda · as of 2026-08-14].
From the filings
Quoted directly from source documents.
The company plans to submit an initial NDA via accelerated approval for platinum-resistant/refractory ovarian cancer in the first quarter of 2027.
“We plan to submit our initial New Drug Application, or NDA, via accelerated approval for platinum resistant/refractory ovarian cancer in the first quarter of 2027.”
SEC MD&A · August 14, 2026
PC14586 was granted FDA Fast Track Designation in October 2020.
“In October 2020, we were granted FDA Fast Track Designation of PC14586 for the treatment of patients with locally advanced or metastatic solid tumors that have a p53 Y220C mutation.”
SEC MD&A · November 9, 2023
The company's cash runway is estimated to fund operations until the end of the second quarter of 2027.
“5 will be sufficient to fund our planned operations until the end of the second quarter of 2027.”
SEC MD&A · March 6, 2026
The company has no approved products and continues to incur significant expenses.
“product candidates approved for sale, and we continue to incur significant research and development and general administrative expenses related to our operations.”
SEC MD&A · November 9, 2023
Risks & what to watch (4)›
Key risks
- Cash runway limited — Cash and equivalents of $12.5M as of June 30, 2026, with runway only until Q2 2027; may need additional financing [sec].
- No approved products — The company has no products approved for sale and relies on successful clinical development and regulatory approval [sec_mda · as of 2023-11-09].
- Clinical development uncertainty — Clinical timelines, costs, and success probabilities are unpredictable and may differ materially from expectations [sec_mda · as of 2025-11-12].
- Increasing operating expenses — Operating expenses are expected to increase significantly as the company advances development and prepares for commercialization [sec_mda · as of 2026-08-14].
What to watch
- NDA submission for PC14586 in platinum-resistant/refractory ovarian cancer, planned for the first quarter of 2027 [sec_mda · as of 2026-08-14].
- Cash runway updates and potential need for additional financing as the company approaches the end of Q2 2027 [sec_mda · as of 2026-03-06].
- Progress of the Phase 2 monotherapy portion of the PYNNACLE study and any data readouts [sec_mda · as of 2026-08-14].
- Regulatory interactions and updates on Fast Track designation benefits for PC14586 [sec_mda · as of 2023-11-09].
Sources: SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run PMV Pharmaceuticals, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available PMV Pharmaceuticals, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
15.8 months
D/E 0.15 · 0% dilution
Lead: Phase 2
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
65
Total value held
$29.3M
| Holder | Shares | Value |
|---|---|---|
| tang capital management llc | 4,245,085 | $5.3M |
| vanguard capital management llc | 3,949,812 | $4.9M |
| euclidean capital llc | 2,627,643 | $3.3M |
| two sigma investments, lp | 1,884,530 | $2.3M |
| adage capital partners gp, l.l.c. | 1,860,000 | $2.3M |
| blackrock, inc. | 874,374 | $1.1M |
| morgan stanley | 864,311 | $1.1M |
| stonepine capital management, llc | 708,102 | $878K |
| walleye capital llc | 671,388 | $833K |
| longaeva partners l.p. | 552,027 | $685K |
Showing top 10 of 65 institutional holders of PMV Pharmaceuticals, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 5.1%
- Days to cover
- 6.5
- Shares short
- 2,633,561
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PMVP short interestGovernance
Frequently asked questions
What is the AI investment thesis for PMV Pharmaceuticals, Inc.?
PMV Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule drugs targeting p53 mutations, with its lead candidate PC14586 in a Phase 1/2 trial for solid tumors with the p53 Y220C mutation.
What is PMV Pharmaceuticals, Inc.'s lead drug candidate?
PMV Pharmaceuticals, Inc.'s most advanced tracked candidate is pc14586 (Phase 2) for Locally advanced or metastatic solid tumors with a p53 Y220C mutation.
Who is the CEO of PMV Pharmaceuticals, Inc.?
Dr. David H. Mack Ph.D. is the chief executive officer of PMV Pharmaceuticals, Inc. (PMVP).
Where is PMV Pharmaceuticals, Inc. headquartered?
PMV Pharmaceuticals, Inc. (PMVP) is headquartered in Princeton, NJ, United States.
What therapeutic areas does PMV Pharmaceuticals, Inc. focus on?
PMV Pharmaceuticals, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.